Ipilimumab

CTLA-4 Inhibitors

Immune checkpoint inhibitors

• Monoclonal IgG antibody
  • Blocks CTLA-4 that suppresses T-cell function interaction with APC
  • CTLA = Cytotoxic T-Lymphocyte-Associated Antigen
• Ipilimumab
  • 3mg/kg every 3 weeks IV
  • 20% response rate
  • High Side Effect profile (Manage with steroids)
    • 50%
    • Enterocolitis
    • Hepatitis
    • Dermatitis
    • Neuropathy
    • Endocrinopathy
  • Not funded in NZ but available in private
• CheckMate 238 - Nivolumab vs Ipilimumab - similar outcomes but Ipilimumab more toxic
• CheckMate 915 Nivolumab and Ipilimumab vs Nivolumab - no benefit but increase toxicity